Nonclinical precedent Request an invite
Species
No relevant species; in vitro human cell/tissue assays only
“There are no pharmacologically relevant animal species to evaluate tebentafusp toxicity.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Why that species
TCR recognizes only human gp100:HLA-A*02:01; anti-CD3 scFv binds human T cells only, not mouse or monkey
“In vitro, the scFv portion of tebentafusp bound to T cells in human PBMCs but did not bind PBMCs from mouse or monkey.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Surrogate molecule
No surrogate; in vitro human-cell approach instead of animal tox
“Tebentafusp can only recognize human HLA; therefore, all nonclinical toxicology studies were conducted in vitro.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: general tox
None (no relevant species; all toxicology studies in vitro)
“Tebentafusp can only recognize human HLA; therefore, all nonclinical toxicology studies were conducted in vitro.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: DART
Not conducted (specificity for human targets)
“Due to the specificity for human targets, embryo-fetal development (EFD) studies cannot be conducted in nonclinical species.”
✓ VerifiedEMA assessment report, p. 30Source ↗
Species: carcinogenicity
Not conducted
“No carcinogenicity or genotoxicity studies have been conducted with tebentafusp-tebn.”
✓ VerifiedUS prescribing informationSource ↗
Surrogate used in
No surrogate used; no relevant animal species, in vitro human-cell assays instead
“Since, tebentafusp is specific for human gp100 and CD3 with no affinity to e.g. monkey, rat or mice, secondary and safety pharmacology was evaluated using in vitro methods on human tissues and cells..”
✓ VerifiedEMA assessment report, p. 25Source ↗

Same question, other multispecifics

Bizengri

zenocutuzumab · HER2 x HER3
Cynomolgus monkey only

Blincyto

blinatumomab · CD19 x CD3
Chimpanzee (only relevant species, limited non-terminal studies) plus mouse with murine surrogate

Columvi

glofitamab · CD20 x CD3
Cynomolgus monkey only

Elrexfio

elranatamab · BCMA x CD3
Cynomolgus monkey only

Epkinly

epcoritamab · CD20 x CD3
Cynomolgus monkey only

Hemlibra

emicizumab · FIXa x FX
Cynomolgus monkey only

Imdelltra

tarlatamab · DLL3 x CD3
Cynomolgus monkey (pivotal); mouse surrogate muS757 for EFD and 1-month study

Korjuny

catumaxomab · EpCAM x CD3
No relevant species; limited single-dose mouse, rat, one cynomolgus; BiLu mouse surrogate

Lunsumio

mosunetuzumab · CD20 x CD3
Cynomolgus monkey only

Lynozyfic

linvoseltamab · BCMA x CD3
Cynomolgus monkey only

Ordspono

odronextamab · CD20 x CD3
Cynomolgus monkey only

Removab

catumaxomab · EpCAM x CD3
No relevant species; in vitro human cells plus mouse surrogate (BiLu); limited single-dose rodent/monkey

Rybrevant

amivantamab · EGFR x MET
Cynomolgus monkey only

Talvey

talquetamab · GPRC5D x CD3
Cynomolgus monkey only (tool molecule for pivotal tox); no rodent tox

Tecvayli

teclistamab · BCMA x CD3
Cynomolgus monkey only (rabbit used for SC local tolerance only)

Vabysmo

faricimab · VEGF-A x Ang-2
Cynomolgus monkey only for pivotal tox (rabbit dropped after early studies)

Ziihera

zanidatamab · HER2 x HER2 (biparatopic)
Cynomolgus monkey only

Summary across all 18 multispecifics →